Cheng, Ann-Lii <br/><br/>
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.  [electronic resource] 

 -  Journal of hepatology  02 2020 
 - 307-319 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2019.09.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Biomarkers, Tumor--blood<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Carcinoma, Hepatocellular--blood<br/>Combined Modality Therapy--methods<br/>Humans<br/>Immune Checkpoint Inhibitors--pharmacology<br/>Immunotherapy--methods<br/>Liver Neoplasms--blood<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Progression-Free Survival<br/>T-Lymphocytes--immunology